BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11284929)

  • 1. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Rubinstein E; Diamantstein L; Yoseph G; Gruzman G; Rubinovitch B; Barzilai A; Keller N
    Clin Microbiol Infect; 2000 Dec; 6(12):678-81. PubMed ID: 11284929
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
    Beyer R; Pestova E; Millichap JJ; Stosor V; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 2000 Mar; 44(3):798-801. PubMed ID: 10681364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ; Jin YF
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG; Hollauer K; Kirchbauer D; Witte W
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal activity of trovafloxacin (CP-99,219).
    Morrissey I
    J Antimicrob Chemother; 1996 Dec; 38(6):1061-6. PubMed ID: 9023654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of moxifloxacin against Staphylococcus aureus.
    Berrington AW; Perry JD; Gould FK
    Clin Microbiol Infect; 2001 Mar; 7(3):161-3. PubMed ID: 11318816
    [No Abstract]   [Full Text] [Related]  

  • 14. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
    Weiss K; Laverdiere M; Restieri C
    J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
    Clark CL; Nagai K; Davies TA; Bozdogan B; Dewasse B; Jacobs MR; Appelbaum PC
    Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
    Rodríguez JC; Llinares F; Royo G
    Chemotherapy; 2001; 47(1):39-42. PubMed ID: 11125231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
    Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.